Royalty Pharma plc (MUN:RPD)

Market Cap	18.83B +53.0%
Revenue (ttm)	2.03B +5.1%
Net Income	656.62M -10.2%
EPS	1.52 -6.8%
Shares Out	n/a
PE Ratio	28.68
Forward PE	7.67
Dividend	0.77 (1.85%)
Ex-Dividend Date	Feb 20, 2026

Volume	n/a
Average Volume	218
Open	41.90
Previous Close	41.85
Day's Range	41.90 - 41.90
52-Week Range	30.41 - 41.90
Beta	n/a
RSI	72.72
Earnings Date	May 6, 2026

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

• Industry: Pharmaceutical Preparations
• Founded: 1996
• Employees: 100
• Stock Exchange: Munich Stock Exchange
• Ticker Symbol: RPD

Financial Performance

In 2025, Royalty Pharma's revenue was $2.38 billion, an increase of 5.06% compared to the previous year's $2.26 billion. Earnings were $770.95 million, a decrease of -10.25%.

Financial numbers in USD